Physician profile
Eric E Jensen
NPI 1235136052
$12,263.77
in general payments reported to CMS, 2019-2025
54 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,856 · 2020: $1,648 · 2021: $1,925 · 2022: $1,882 · 2023: $1,715 · 2024: $1,780 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,951.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,765.89 | 2019-2025 | Repatha, Evenity, Prolia |
| Pfizer INC. | $1,330.19 | 2019-2025 | |
| Abbvie INC. | $1,167.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $942.09 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $785.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.82 | 2019-2025 | Jardiance, Ofev |
| Abbott Laboratories | $647.02 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $485.67 | 2021-2025 | |
| Glaxosmithkline, LLC. | $363.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $339.12 | 2019-2023 | |
| Amarin Pharma, INC. | $329.77 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $315.75 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $305.54 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $278.40 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $253.34 | 2019-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.